Answers are grounded in this paper and cite their sources.
Polyendocrine metabolic ovarian syndrome (PMOS), formerly polycystic ovary syndrome, is conventionally diagnosed through reproductive manifestations, but its prediagnostic anthropometric trajectory remains incompletely characterized. We analyzed de-identified electronic health records from a federated US network. Across 1,929 conditions and 15,087,821 individuals, PMOS combined high diagnostic weight (94.3 kg) with five-year weight gain (10.0 kg, 15.6%), resembling insulin resistance, metabolic syndrome and obesity. Among 104,003 cases (mean diagnostic age 30.9 years, s.d. 9.5), BMI exceeded matched controls’ at the earliest observation, 15 years before first recorded diagnosis (23 vs 20 kg/m², P < 0.001). Weight rose from 85.9 to 94.0 kg over five years (8.1 kg, 9.4%) and exceeded controls’ by 17.9 kg at diagnosis (94.0 vs 76.1 kg, P < 0.001). Of 809,719 women with BMI recorded at ages 5–20, 19,681 subsequently received a PMOS diagnosis. Ten-year cumulative incidence across standardized CDC/AAP categories rose from 2.8% at healthy BMI to 17.3% in class III severe obesity (unadjusted RR 6.2, 95% CI 5.9–6.6). Under fixed thresholds, Black representation rose from 11.1% to 26.5% across these categories (2.4-fold, P < 0.001 for each band versus healthy BMI). In 1,416 matched pairs with AI-extracted serial measurements, cases had greater estimated non-lean mass (55.4 vs 45.6 kg) and lower lean-mass proportion (52.0% vs 55.8%, both P < 0.001). Estimated non-lean mass accounted for approximately 72% of the 14.1 kg weight gap near diagnosis. BMI divergence preceded recorded diagnosis, PMOS incidence rose with childhood and adolescent BMI, and estimated non-lean mass explained most of the weight gap near diagnosis.
No takes yet. Share an insight, caveat, or question.
Murugadoss et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: